{
  "id": 4109239,
  "title": "PTC Therapeutics director Michael Schmertzler sells $1.8m in shares",
  "url": "https://urgent.news/2026/08/29/ptc-therapeutics-director-michael-schmertzler-sells-1-8m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-29T04:16:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ptc-therapeutics-director-michael-schmertzler-sells-18m-in-shares-93CH-4881935"
  },
  "original_language": "en",
  "account": "PTC Therapeutics director Michael Schmertzler sold approximately $1.8 million worth of company shares in late August. The transactions occurred between August 26 and August 27, 2026, with shares traded at prices ranging from $71.55 to $73.18 per share. Schmertzler, along with Section Six Partners, L.P., executed these sales through a pre-arranged Rule 10b5-1 trading plan. The company's stock currently trades at $70.09, having delivered a 42% return over the past year, despite a 8% decline year-to-date.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Monopar Therapeutics director Raymond Anderson sells $351,835 in stock",
        "url": "https://urgent.news/2026/08/29/monopar-therapeutics-director-raymond-anderson-sells-351-835-in-stock",
        "published": "2026-08-29T00:01:04.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}